Key Financial Data Of Reporting Company

Oncolys BioPharma Inc. - Filing #7342826

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2021-12-31
2021-01-01 to
2021-12-31
2020-01-01 to
2020-12-31
As at
2020-12-31
As at
2019-12-31
2019-01-01 to
2019-12-31
Key financial data of reporting company
Business results of reporting company
Net sales
63,038,000 JPY
976,182,000 JPY
642,494,000 JPY
314,179,000 JPY
1,303,844,000 JPY
Ordinary profit (loss)
-1,913,816,000 JPY
-1,163,008,000 JPY
-1,500,888,000 JPY
-1,723,537,000 JPY
-539,177,000 JPY
Profit (loss)
-1,938,505,000 JPY
-1,148,938,000 JPY
-1,615,439,000 JPY
-2,095,087,000 JPY
-912,346,000 JPY
Equity in earnings (losses) of affiliates if equity method is applied
JPY
JPY
JPY
JPY
JPY
Share capital
3,623,165,000 JPY
3,000,000,000 JPY
9,039,516,000 JPY
7,436,537,000 JPY
7,121,273,000 JPY
Total number of issued shares
19,717,100 xbrli:shares
17,405,200 xbrli:shares
17,405,200 xbrli:shares
14,641,900 xbrli:shares
14,331,300 xbrli:shares
Net assets
1,474,097,000 JPY
2,159,269,000 JPY
3,593,992,000 JPY
2,003,325,000 JPY
3,454,048,000 JPY
Total assets
2,040,598,000 JPY
2,650,959,000 JPY
4,291,876,000 JPY
2,796,413,000 JPY
4,380,056,000 JPY
Net assets per share
74.35
124.20
206.86
136.43
240.71
Dividend paid per share
Interim dividend paid per share
Basic earnings (loss) per share
-108.92
-66.31
-95.50
-145.58
-65.55
Diluted earnings per share
Equity-to-asset ratio
0.715 xbrli:pure
0.812 xbrli:pure
0.836 xbrli:pure
0.714 xbrli:pure
0.787 xbrli:pure
Rate of return on equity
xbrli:pure
xbrli:pure
xbrli:pure
xbrli:pure
xbrli:pure
Price-earnings ratio
xbrli:pure
xbrli:pure
xbrli:pure
xbrli:pure
xbrli:pure
Payout ratio
xbrli:pure
xbrli:pure
xbrli:pure
xbrli:pure
xbrli:pure
Net cash provided by (used in) operating activities
-1,336,922,000 JPY
-1,717,135,000 JPY
-1,741,827,000 JPY
-1,465,199,000 JPY
-238,228,000 JPY
Net cash provided by (used in) investing activities
-5,392,000 JPY
20,117,000 JPY
-942,000 JPY
-37,577,000 JPY
-4,442,000 JPY
Net cash provided by (used in) financing activities
1,142,542,000 JPY
-113,830,000 JPY
3,091,384,000 JPY
242,261,000 JPY
1,123,312,000 JPY
Cash and cash equivalents
1,287,763,000 JPY
1,466,201,000 JPY
3,209,635,000 JPY
1,822,850,000 JPY
3,097,514,000 JPY
Number of employees
34 xbrli:pure
33 xbrli:pure
33 xbrli:pure
32 xbrli:pure
27 xbrli:pure
Average number of temporary employees
6 xbrli:pure
4 xbrli:pure
3 xbrli:pure
5 xbrli:pure
5 xbrli:pure
Total shareholder return
0.548 xbrli:pure
0.510 xbrli:pure
0.511 xbrli:pure
1.454 xbrli:pure
1.860 xbrli:pure
Total return on share price index
1.789 xbrli:pure
1.395 xbrli:pure
1.430 xbrli:pure
1.268 xbrli:pure
1.181 xbrli:pure

Talk to a Data Expert

Have a question? We'll get back to you promptly.